Blog Header

In: Industry trends

18 Feb, 2014Computational Drug Discovery: Traditional Methods Aren’t Enough!


Traditional drug discovery is expensive, inefficient, and has huge barriers to entry. Big pharmaceutical companies continue to struggle to cope with tight margins…

Read More

11 Feb, 2014Hit your target with fragment-based drug discovery


If you validated the drug target to cure a disease, but can’t hit it efficiently with high-throughput screening (HTS), fragment-based drug discovery could be…

Read More

04 Feb, 2014Sequencing and Drug Discovery: How does Illumina’s new $1000 human genome affect drug discovery?


Illumina recently announced the $1000 solution for the sequencing of the human genome in the form of its new instrument, the HiSeqX. This…

Read More

23 Jan, 20143 Ways to Avoid Drowning in Big Data


This is the third in a three-part series by Dr. Heather Buschman on Big Data in the pharmaceutical and biotechnology industries. Check out…

Read More

16 Jan, 20143 Bottlenecks Keeping Big Data from Big Results


This is the second in a three-part series by Dr. Heather Buschman on Big Data in the pharmaceutical and biotechnology industries. Check out…

Read More